Re: Effect of Longer-interval Versus Standard Dosing of Zoledronic Acid on Skeletal Events in Patients with Bone Metastases.
Sign Up to like & getrecommendations! Published in 2018 at "European urology"
DOI: 10.1016/j.eururo.2017.11.007
Abstract: This phase 3 randomised controlled trial was designed to test whether 12-weekly zoledronate is non-inferior to 4-weekly zoledronate in terms of the risk of skeletal events. The study population comprised 1822 patients with metastatic bone… read more here.
Keywords: longer interval; standard dosing; skeletal events; versus standard ... See more keywords